NervGen Pharma Corp.

Recent News

  • NervGen Pharma Announces Results of Annual General Meeting of Shareholders

    All resolutions submitted for approval were passed by shareholdersVancouver, British Columbia--(Newsfile Corp. - September 29, 2022) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF), a clinical stage biotech company dedicated to developing a first-in-class neuroreparative drug to treat nervous system damage, announces the results of its Annual General Meeting of Shareholders ("AGM") held on September 28, 2022. "We appreciate the support from our shareholders demonstrated at this AGM," stated Bill Radvak, NervGen's Executive Chairman and Interim CEO. "With our Phase...

    2022-09-29 8:30 AM EDT
  • NervGen Pharma Announces Leadership Transition

    Bill Radvak, Co-founder and Executive Chairman of the Board, appointed interim Chief Executive Officer Dr. Adam Rogers, member of the Board of Directors, appointed interim President Paul Brennan to step down as President & Chief Executive Officer and member of the Board of Directors; will serve as a strategic advisor for a transition periodVancouver, British Columbia--(Newsfile Corp. - September 22, 2022) - NervGen Pharma Corp. (OTCQX: NGENF) (TSXV: NGEN), a clinical stage biotech company dedicated to developing a first-in-class neuroreparative...

    2022-09-22 7:21 PM EDT
  • NervGen Pharma Announces Appointment of Dr. Matvey Lukashev as Vice President, Research and Preclinical Development

    Expands research capabilities aiming to build pipeline of proprietary compounds for nervous system repairDr. Lukashev brings over 20 years' experience including work at Biogen and the ALS Therapy Development Institute Vancouver, British Columbia--(Newsfile Corp. - September 12, 2022) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, is pleased to announce the appointment of Matvey Lukashev, PhD, as the Company's...

    2022-09-12 8:30 AM EDT
  • NervGen Pharma Presenting at Upcoming Military Health System Research Symposium and the 61st International Spinal Cord Society Annual Scientific Meeting

    Vancouver, British Columbia--(Newsfile Corp. - September 8, 2022) -  NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, will present a poster at the upcoming Military Health System Research Symposium (MHSRS) on September 12-15, 2022 and will also present an oral presentation at the 61st International Spinal Cord Society (ISCoS) Annual Scientific Meeting on September 17, 2022. NervGen's Director of Research,...

    2022-09-08 8:30 AM EDT
  • NervGen Pharma Reports Second Quarter 2022 Results and Provides Corporate Update

    Cash position enhanced by over $22 million due to private placement and exercise of warrants and optionsDosing in third dose cohort of multiple ascending dose (MAD) portion of Phase 1 clinical trial ongoingDiscussions ongoing with FDA regarding partial clinical holdUpdate provided on developments with US Government related to non-dilutive funding in spinal cord injury and traumatic brain injury Vancouver, British Columbia--(Newsfile Corp. - August 10, 2022) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical...

    2022-08-10 8:30 AM EDT
  • NervGen Presenting Study Design for Upcoming Phase 1b/2a in Alzheimer's Disease at the 2022 Alzheimer's Association International Conference

    Vancouver, British Columbia--(Newsfile Corp. - August 2, 2022) - NervGen Pharma Corp., (TSXV: NGEN) (OTCQX: NGENF), a clinical stage biotech company dedicated to developing a first-in-class neuroreparative drug to treat nervous system damage, will present the study design for its upcoming Phase 1b/2a Alzheimer's disease clinical trial at the 2022 Alzheimer's Association International Conference (AAIC) on August 3, 2022. NervGen's Chief Medical Officer, Dr. Daniel Mikol, will present a poster summarizing unblinded data from the single ascending dose (SAD) cohort...

    2022-08-02 8:30 AM EDT
  • NervGen Pharma Grants Stock Options

    Vancouver, British Columbia--(Newsfile Corp. - July 15, 2022) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing a first-in-class neuroreparative drug to treat nervous system damage, announced that the Company has granted 150,000 incentive stock options to a director exercisable at a price of $1.99 per share for a period of five years and that vest equally every three months over a one-year period. All options have been granted...

    2022-07-15 8:49 AM EDT
  • NervGen Pharma Closes US$15MM Private Placement and Appoints Dr. Adam Rogers to Board of Directors

    Vancouver, British Columbia--(Newsfile Corp. - July 14, 2022) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" the "Company"), a clinical stage biotech company dedicated to developing a first-in-class neuroreparative drug to treat nervous system damage, announced that it has closed its previously announced non-brokered private placement (the "Private Placement") of 10,150,000 units of the Company at a price of US$1.50 per unit (the "Unit Price"), for aggregate gross proceeds to the Company of US$15,225,000. In connection with the Private...

    2022-07-14 9:05 AM EDT